240 related articles for article (PubMed ID: 36739065)
41. Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Andrews SW; Kabrah S; May JE; Donaldson C; Morse HR
Br J Biomed Sci; 2013; 70(3):110-20. PubMed ID: 24273897
[TBL] [Abstract][Full Text] [Related]
42. Targeting the Microenvironment for Treating Multiple Myeloma.
Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976
[TBL] [Abstract][Full Text] [Related]
43. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
[TBL] [Abstract][Full Text] [Related]
44. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
Cheung WC; Van Ness B
Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
[TBL] [Abstract][Full Text] [Related]
45. Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
Sharma NS; Choudhary B
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002311
[TBL] [Abstract][Full Text] [Related]
46. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
47. An Overview of Organoid and 3-Dimensional Models in Multiple Myeloma.
Rodriguez C
Cancer J; 2021 May-Jun 01; 27(3):239-246. PubMed ID: 34549913
[TBL] [Abstract][Full Text] [Related]
48. The microenvironment and molecular biology of the multiple myeloma tumor.
Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
[TBL] [Abstract][Full Text] [Related]
49. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
[TBL] [Abstract][Full Text] [Related]
50. Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of Resistance in Multiple Myeloma.
Papadas A; Asimakopoulos F
Handb Exp Pharmacol; 2018; 249():251-288. PubMed ID: 28315070
[TBL] [Abstract][Full Text] [Related]
52. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Hayashi T; Hideshima T; Akiyama M; Richardson P; Schlossman RL; Chauhan D; Munshi NC; Waxman S; Anderson KC
Mol Cancer Ther; 2002 Aug; 1(10):851-60. PubMed ID: 12492118
[TBL] [Abstract][Full Text] [Related]
53. Bone marrow myeloid cells in regulation of multiple myeloma progression.
Herlihy SE; Lin C; Nefedova Y
Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
[TBL] [Abstract][Full Text] [Related]
54. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
55. Significance of a tumor microenvironment-mediated P65-miR-30a-5p-BCL2L11 amplification loop in multiple myeloma.
Xie L; Wei J; Gao Z; Huang H; Ju S; Wang X
Exp Cell Res; 2022 Jun; 415(1):113113. PubMed ID: 35339472
[TBL] [Abstract][Full Text] [Related]
56. Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment.
Tian X; Sun M; Wu H; Chen C; Li H; Qiu S; Wang T; Han J; Xiao Q; Chen K
Leuk Res; 2021 Jun; 105():106566. PubMed ID: 33848709
[TBL] [Abstract][Full Text] [Related]
57. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.
Swamydas M; Murphy EV; Ignatz-Hoover JJ; Malek E; Driscoll JJ
J Hematol Oncol; 2022 Feb; 15(1):17. PubMed ID: 35172851
[TBL] [Abstract][Full Text] [Related]
58. Roles of noncoding RNAs in drug resistance in multiple myeloma.
Li J; Zou J; Wan X; Sun C; Chu Z; Hu Y
J Cell Physiol; 2020 Nov; 235(11):7681-7695. PubMed ID: 32324301
[TBL] [Abstract][Full Text] [Related]
59. [Advances in Modeling of Multiple Myeloma in Mice].
Gu XY; Tang WJ; Li Y; Zhang L; Zheng YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):512-518. PubMed ID: 37407542
[TBL] [Abstract][Full Text] [Related]
60. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.
Colombo M; Garavelli S; Mazzola M; Platonova N; Giannandrea D; Colella R; Apicella L; Lancellotti M; Lesma E; Ancona S; Palano MT; Barbieri M; Taiana E; Lazzari E; Basile A; Turrini M; Pistocchi A; Neri A; Chiaramonte R
Haematologica; 2020 Jul; 105(7):1925-1936. PubMed ID: 31582544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
